首页> 美国卫生研究院文献>Bioengineering Translational Medicine >Engineered heparins as new anticoagulant drugs
【2h】

Engineered heparins as new anticoagulant drugs

机译:工程肝素作为新的抗凝药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Heparin is an anionic polysaccharide that is widely used as a clinical anticoagulant. This glycosaminoglycan is prepared from animal tissues in metric ton quantities. Animal‐sourced heparin is also widely used in the preparation of low molecular weight heparins that are gaining in popularity as a result of their improved pharmacological properties. The recent contamination of pharmaceutical heparin together with concerns about increasing demand for this life saving drug and the fragility of the heparin supply chain has led the scientific community to consider other potential sources for heparin. This review examines progress toward the preparation of engineered heparins through chemical synthesis, chemoenzymatic synthesis, and metabolic engineering.
机译:肝素是一种阴离子多糖,广泛用作临床抗凝剂。这种糖胺聚糖是从动物组织中以公吨数量制备的。动物源性肝素还被广泛用于制备低分子量肝素,由于其改善的药理特性而日益普及。最近药用肝素的污染,以及对该救生药物的需求不断增长以及肝素供应链的脆弱性的担忧,促使科学界考虑使用肝素的其他潜在来源。这篇综述探讨了通过化学合成,化学酶促合成和代谢工程制备工程肝素的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号